长链非编码RNA在胶质瘤替莫唑胺耐药中的研究进展

Research progress of long non-coding RNA in Temozolomide resistant glioma

恶性胶质瘤是最常见的原发性恶性脑肿瘤,其治疗方法以放化疗为主。替莫唑胺(TMZ)是治疗胶质瘤的化疗药物之一,是一种烷化剂,疗效在临床上获得了肯定,被广泛应用于胶质瘤的治疗。TMZ对胶质瘤的治疗效果很大程度上受到了快速耐药性的限制,因此胶质瘤发生耐药性一直是临床治疗中的难点和关键问题。近年来,大量的文章揭示了长链非编码RNA(lncRNA)在肿瘤细胞中表达异常,并且与肿瘤侵袭转移、术后复发、耐药及临床预后等方面有着密切的关系。文章就长链非编码RNA在胶质瘤对TMZ耐药中的可能作用机制进行综述。

Malignant glioma is the most common primary malignant brain tumor, and its treatment is usually related to chemotherapy. Nowadays, temozolomide(TMZ) is one of chemotherapeutic drugs used in gliomas treatment. It is a alkylating agent, and its curative effect has been clinically affirmed. It is widely used in the treatment of glioma, and it is also one of the first line clinical chemotherapy drugs. The therapeutic effect of TMZ on glioma is largely limited by rapid drug resistance, so the occurrence of drug resistance in glioma has always been a difficult and key problem in clinical treatment. In recent years, more and more studies have found that long non-coding RNA(lncRNA) is often proved to show abnormal expression in tumor cells, and has a close relationship with tumor metastasis, postoperative recurrence, drug resistance and clinical prognosis evaluation. This paper summarized the possible mechanism of the role of long non-coding RNA in glioma resistance to TMZ, and the aim was to understand the mechanism of the effect of LncRNA on TMZ drug resistance in glioma and to provide theoretical support for follow up research and development.